Remission, Relapse, and Thyroid-Related Parameters Measurement at Discontinuation of Low-Dose Anti-Thyroid Drugs in Graves’ Disease
Endocrinology and Metabolism · 31.10.2026 · 41 (5) · 686-695
DOI: 10.3803/enm.2025.2771 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology and Metabolism, erschienen am 31.10.2026. Verfasst von Nami Suzuki und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Ito Hospital, Tokyo, Japan. n-suzuki@ito-hospital.jp. Hauptthemen laut MEDLINE: Graves Disease, Antithyroid Agents, Thyroid Gland. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
This study aimed to elucidate the relationship between thyroid-related parameters and the prognosis of Graves’ disease (GD).
Methods
This retrospective cohort study included patients newly diagnosed with GD between January 2009 and December 2010. We applied multivariable Cox proportional hazard models to estimate the hazard ratio (HR) and 95% confidence intervals (CI) for the relationships between the parameters at anti-thyroid drug (ATD) discontinuation and GD relapses. We also developed prediction models for GD prognosis based on parameters at ATD initiation and discontinuation using logistic regression and machine learning algorithm (gradient-boosting machine [GBM]).
Results
The median observation period was 11.3 years. In 1,508 patients who discontinued ATDs after the first course, 1,073 remained in remission, whereas 435 relapsed within a median of 20 months (interquartile range, 10.0 to 49.7). In the Cox model, we found that patients with younger age, higher thyroid stimulating hormone (TSH) receptor antibody (TRAb), and lower TSH levels at ATD discontinuation were more likely to relapse than those without (per 5-year increase in age: HR, 0.92 [95% CI, 0.88 to 0.95]; per 1-unit increase in TSH: HR, 0.86 [95% CI, 0.79 to 0.94]; per 1-unit increase in TRAb: HR, 1.15 [95% CI, 1.06 to 1.24]). Both logistic regression and GBM demonstrated similar predictive performance (area under the curve, 0.61 to 0.63), showing that age and parameters at both ATD initiation and discontinuation contribute to GD relapse.
Conclusion
TRAb levels at ATD discontinuation may contribute to the prognosis of GD, but they are not sufficient on their own to predict relapse.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Ito Hospital, Tokyo, Japan. n-suzuki@ito-hospital.jp.
- Department of Health Promotion and Human Behavior, Graduate School of Medicine and School of Public Health, Kyoto University, Tokyo, Japan.
- Department of Internal Medicine, Ito Hospital, Tokyo, Japan.
- Department of Surgery, Ito Hospital, Tokyo, Japan.
Zitieren
APA
Suzuki, N., Inoue, K., Watanabe, N., Noh, J. Y., Yoshihara, A., Fukushita, M., Matsumoto, M., Koshibu, M., Hirose, R., Iida, T., Sugino, K., & Ito, K. (2026). Remission, Relapse, and Thyroid-Related Parameters Measurement at Discontinuation of Low-Dose Anti-Thyroid Drugs in Graves’ Disease. Endocrinology and Metabolism, 41(5), 686-695. https://doi.org/10.3803/enm.2025.2771
Vancouver
Suzuki N, Inoue K, Watanabe N, Noh JY, Yoshihara A, Fukushita M, et al. Remission, Relapse, and Thyroid-Related Parameters Measurement at Discontinuation of Low-Dose Anti-Thyroid Drugs in Graves’ Disease. Endocrinology and Metabolism. 2026;41(5):686-695. doi:10.3803/enm.2025.2771
BibTeX
@article{Suzuki2026,
author = {Suzuki, Nami and Inoue, Kosuke and Watanabe, Natsuko and Noh, Jaeduk Yoshimura and Yoshihara, Ai and Fukushita, Miho and Matsumoto, Masako and Koshibu, Masakazu and Hirose, Rei and Iida, Tatsuya and Sugino, Kiminori and Ito, Koichi},
title = {Remission, Relapse, and Thyroid-Related Parameters Measurement at Discontinuation of Low-Dose Anti-Thyroid Drugs in Graves’ Disease},
journal = {Endocrinology and Metabolism},
year = {2026},
volume = {41},
number = {5},
pages = {686--695},
doi = {10.3803/enm.2025.2771}
}
EUVIMED